- PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager
- PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
- PharmaEssentia Appoints Fred Paster as Head of Commercial
- BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO
- CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 597.00 |
---|---|
High | 605.00 |
Low | 572.00 |
Bid | 577.00 |
Offer | 578.00 |
Previous close | 567.00 |
Average volume | 5.39m |
---|---|
Shares outstanding | 340.91m |
Free float | 262.74m |
P/E (TTM) | 411.63 |
Market cap | 193.29bn TWD |
EPS (TTM) | 1.38 TWD |
Data delayed at least 20 minutes, as of Jul 08 2024.
More ▼